baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

ORION CLASS B/ FI0009014377 /

- -	Chg. -	Volume	Bid8:30:00 PM	Ask8:30:00 PM	Market Capitalization	Dividend Y.	P/E Ratio
36.070EUR	-	- Turnover: -	-Bid Size: -	-Ask Size: -	3.86 bill.EUR	4.49%	23.45

GlobeNewswire 01-26 Additional ODM-208/MK-5684 Phase II data presented at ASCO-GU 2024

GlobeNewswire 01-08 Orion and Glykos announce research collaboration and licensing agreement to develop next-generation ...

GlobeNewswire 01-05 Orion and MSD Announce Initiation of Two Phase 3 Trials Evaluating ODM-208/MK5684 in Certain Patient...

GlobeNewswire 2023-12-27 NEJM Evidence publishes results from Phase I/IIa CYPIDES trial with ODM-208

GlobeNewswire 2023-11-15 Orion Research Foundation grants EUR 1,112,000 for research in 2024

GlobeNewswire 2022-03-24 Orion is planning to refocus its R&D – in the future focus would be on cancer and pain

GlobeNewswire 2022-02-18 Results from an Ongoing Phase I/II CYPIDES Trial of ODM-208 Presented at ASCO-GU

GlobeNewswire 2022-02-17 Darolutamide plus androgen deprivation therapy and docetaxel significantly increases overall surviva...

GlobeNewswire 2021-12-03 ARASENS trial with darolutamide in combination with docetaxel and androgen deprivation therapy meets...

GlobeNewswire 2021-06-09 Orion’s Clinical Trial Shows Significant Improvement for Chronic Pain Patients Using Virtual Reality...

GlobeNewswire 2019-12-09 Orion presented data on oral levosimendan at the 30th International Symposium on ALS/MND

GlobeNewswire 2019-07-31 U.S. FDA approves darolutamide, a new treatment for men with non-metastatic castration-resistant pro...

GlobeNewswire 2019-06-19 1,767 Orion Corporation A shares converted into B shares

GlobeNewswire 2019-06-11 Change in Orion Corporation's holding of treasury shares

GlobeNewswire 2019-06-06 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ori...

GlobeNewswire 2019-06-03 Pawar Law Group Reminds Investors of Deadline in Securities Class Action Lawsuit Against Sprint Corp...

GlobeNewswire 2019-05-31 2019 American Society of Clinical Oncology (ASCO) Annual Meeting - Darolutamide data presented

GlobeNewswire 2019-05-30 ORION NOTICE: Rosen, a Widely Recognized Law Firm, Reminds Orion Group Holdings, Inc. Investors of I...

GlobeNewswire 2019-05-30 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ori...

GlobeNewswire 2019-05-22 S DEADLINE ALERT: Pawar Law Group Reminds Investors of Deadline in Securities Class Action Lawsuit A...

GlobeNewswire 2019-05-22 ORN JUNE 10 DEADLINE: Pawar Law Group Reminds Investors of Deadline in Securities Class Action Laws...

GlobeNewswire 2019-05-22 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ori...

GlobeNewswire 2019-05-21 Orion Corporation: Managers' transactions - Eija Ronkainen

GlobeNewswire 2019-05-17 ORION GROUP LAWSUIT FILED: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Agains...

GlobeNewswire 2019-05-17 Orion Corporation: Managers' transactions - Riikka Westerlund

ORION CLASS B/ FI0009014377 /

If you wish to receive reply to your feedback, please provide your email address.